Dr. Anil R. Balani, MD

Dr. Balani practices at Capital Health Medical Center - Hopewell in Pennington, New Jersey, part of Capital Health System.

Dr. Balani's NPI, 1972779098, was assigned on May 8, 2008. Dr. Balani graduated from State University of New York at Stony Brook, School of Medicine in 2002. Dr. Balani holds New Jersey license 25MA08408000.

Dr. Balani's primary practice is Capital Health Medical Center - Hopewell, at One Capital Way, Pennington, NJ 08534 in Mercer County. The practice phone is (609) 303-4000. Dr. Balani also practices at Capital Health Medical Center - Hopewell, 1 Capital Way, Pennington, NJ 08534.

Dr. Balani's primary practice is Capital Health Medical Center - Hopewell in Pennington, New Jersey, part of Capital Health System. Dr. Balani is also affiliated with Capital Health Regional Medical Center. The medical group on file is Capital Health Medical Group. Dmand AI also links Dr. Balani to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Balani practices, 3 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Balani's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dmand AI has Dr. Balani's licenses on file in 3 states: New Jersey, New York and Pennsylvania.

CMS data shows 274 Medicare services from Dr. Balani across 7 procedure codes in 2024, for 173 Medicare patients. Medicare paid $30,108 for them.

CMS counts 173 Medicare patients who saw Dr. Balani in 2024. The largest group is 65 to 74, with 104 patients. 75% of them have high cholesterol, and 65% have high blood pressure. 20% are also on Medicaid. Their average risk score is 1.33, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Balani's median patient age at 57, with 54% women.

In 2024, Dr. Balani wrote 597 Medicare Part D claims for 182 patients. 63% of them were for generic drugs. CMS names the drug for 493 of them, across 15 drugs with 11 or more claims each, at $2,449,409 in total drug cost. In 2023, CMS named 437 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Balani for performance year 2024, reported through an alternative payment model (APM). Dr. Balani accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 49 procedures of colonoscopy by Dr. Balani, more than 63% of the clinicians it reports for that procedure.

Dmand AI links Dr. Balani to 2 clinical trials. Conditions studied include Colitis, Ulcerative and Colitis. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Balani that name 2 trials.

CMS Open Payments shows 210 general payments to Dr. Balani from 16 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 87% of the total. Abbvie Inc. paid the most, $99,657. It also lists 4 research payments totaling $1,993 from 2018 to 2020, naming 2 clinical trials.

Dr. Balani graduated from State University of New York at Stony Brook, School of Medicine in 2002.